| Dr Frank Edmund Visco Jr, OD, MS | |
|
1284 Dryden Rd, Ithaca, NY 14850-8795 | |
| (607) 257-1066 | |
| (607) 257-1378 |
| Full Name | Dr Frank Edmund Visco Jr |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 19 Years |
| Location | 1284 Dryden Rd, Ithaca, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548350358 | NPI | - | NPPES |
| 007249 | Other | NY | NY OPTOMETRIST LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WC0802X | Optometrist - Corneal And Contact Management | TUV007249 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Edward G Bryant Iv Od Pllc | 0840445540 | 3 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Brain cancer patients may live longer thanks to a new cancer-detection method developed by researchers at the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and the MUHC, and Polytechnique Montréal.
The development of a new cell-culture system that mimics how specific nerve cell fibers in the brain become coated with protective myelin opens up new avenues of research about multiple sclerosis. Initial findings suggest that myelin regulates a key protein involved in sending long-distance signals.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.
› Verified 8 days ago
| Provider Name | Edward G Bryant Iv Od Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1912241175 PECOS PAC ID: 0840445540 Enrollment ID: O20130304000112 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Brain cancer patients may live longer thanks to a new cancer-detection method developed by researchers at the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and the MUHC, and Polytechnique Montréal.
The development of a new cell-culture system that mimics how specific nerve cell fibers in the brain become coated with protective myelin opens up new avenues of research about multiple sclerosis. Initial findings suggest that myelin regulates a key protein involved in sending long-distance signals.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frank Edmund Visco Jr, OD, MS 3534 State Route 215, Cortland, NY 13045-9440 Ph: (832) 264-9571 | Dr Frank Edmund Visco Jr, OD, MS 1284 Dryden Rd, Ithaca, NY 14850-8795 Ph: (607) 257-1066 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Brain cancer patients may live longer thanks to a new cancer-detection method developed by researchers at the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and the MUHC, and Polytechnique Montréal.
The development of a new cell-culture system that mimics how specific nerve cell fibers in the brain become coated with protective myelin opens up new avenues of research about multiple sclerosis. Initial findings suggest that myelin regulates a key protein involved in sending long-distance signals.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.
› Verified 8 days ago
Kristy May Dean, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1284 Dryden Rd, Ithaca, NY 14850 Phone: 607-257-1066 Fax: 607-257-1378 | |
Tamara Stockwin, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 10 Brentwood Dr, Suite A, Ithaca, NY 14850 Phone: 607-257-5599 Fax: 607-257-3972 | |
Larry B Wallace, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 322 N Aurora St, Ithaca, NY 14850 Phone: 607-277-4749 Fax: 607-277-5216 | |
Ithaca Eye Care Optometry Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 414 E Upland Rd, Suite A, Ithaca, NY 14850 Phone: 610-613-9080 | |
Dr. Alana Curran, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 322 N Aurora St, Ithaca, NY 14850 Phone: 607-246-8466 | |
Westtown Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 609 W Clinton St, Ithaca, NY 14850 Phone: 607-272-7775 Fax: 607-272-7776 | |
Dr Melissa Walters Optometrist Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2230 N Triphammer Rd, Ithaca, NY 14850 Phone: 607-391-0343 Fax: 607-241-9951 |